2013 Q4 Form 10-Q Financial Statement

#000114519713000035 Filed on November 07, 2013

View on sec.gov

Income Statement

Concept 2013 Q4 2013 Q3 2012 Q3
Revenue $68.53M $61.10M $54.75M
YoY Change 18.51% 11.6% 22.78%
Cost Of Revenue $35.50M $33.71M $30.36M
YoY Change 9.23% 11.02% 16.63%
Gross Profit $33.02M $27.40M $24.39M
YoY Change 30.41% 12.32% 31.4%
Gross Profit Margin 48.18% 44.83% 44.55%
Selling, General & Admin $26.40M $38.94M $26.30M
YoY Change 3.13% 48.04% 11.02%
% of Gross Profit 79.96% 142.13% 107.84%
Research & Development $6.400M $5.771M $6.559M
YoY Change 10.34% -12.01% 41.42%
% of Gross Profit 19.38% 21.07% 26.89%
Depreciation & Amortization $2.950M $3.100M $2.590M
YoY Change 0.34% 19.69% -8.48%
% of Gross Profit 8.93% 11.32% 10.62%
Operating Expenses $32.80M $44.71M $32.86M
YoY Change 4.46% 36.05% 16.0%
Operating Profit $218.0K -$17.31M -$8.471M
YoY Change -103.58% 104.38% -13.28%
Interest Expense -$2.900M $100.0K -$3.900M
YoY Change -27.5% -102.56% 2.63%
% of Operating Profit -1330.28%
Other Income/Expense, Net -$3.972M -$3.918M
YoY Change 1.38% 3.27%
Pretax Income -$2.700M -$21.29M -$12.39M
YoY Change -73.27% 71.81% -8.65%
Income Tax -$200.0K $5.000K $28.00K
% Of Pretax Income
Net Earnings -$2.500M -$21.29M -$12.42M
YoY Change -75.48% 71.46% -8.44%
Net Earnings / Revenue -3.65% -34.84% -22.68%
Basic Earnings Per Share
Diluted Earnings Per Share -$45.70K -$390.8K -$258.3K
COMMON SHARES
Basic Shares Outstanding 54.54M shares 54.42M shares 47.99M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2013 Q4 2013 Q3 2012 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $149.7M $153.9M $63.40M
YoY Change 161.26% 142.74% -38.92%
Cash & Equivalents $149.7M $153.9M $63.44M
Short-Term Investments
Other Short-Term Assets $5.900M $5.900M $5.600M
YoY Change 31.11% 5.36% 51.35%
Inventory $9.464M $5.395M $15.09M
Prepaid Expenses
Receivables $33.07M $34.47M $30.15M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $198.2M $199.7M $114.2M
YoY Change 80.28% 74.79% -17.86%
LONG-TERM ASSETS
Property, Plant & Equipment $32.36M $31.40M $24.91M
YoY Change 27.28% 26.05% 36.12%
Goodwill $37.40M $37.54M $37.54M
YoY Change -0.37% 0.0% 0.09%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.825M $1.721M $2.333M
YoY Change -17.12% -26.23% -16.68%
Total Long-Term Assets $89.76M $89.81M $89.14M
YoY Change 1.85% 0.76% -0.14%
TOTAL ASSETS
Total Short-Term Assets $198.2M $199.7M $114.2M
Total Long-Term Assets $89.76M $89.81M $89.14M
Total Assets $288.0M $289.5M $203.4M
YoY Change 45.39% 42.34% -10.93%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $19.36M $15.12M $16.22M
YoY Change 106.8% -6.78% 88.56%
Accrued Expenses $19.48M $30.02M $17.82M
YoY Change 2.24% 68.48% 39.19%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00 $14.13M
YoY Change -100.0% -100.0%
Total Short-Term Liabilities $42.37M $48.29M $49.34M
YoY Change -12.24% -2.12% 98.96%
LONG-TERM LIABILITIES
Long-Term Debt $113.7M $111.1M $101.5M
YoY Change 9.56% 9.46% -4.5%
Other Long-Term Liabilities $1.943M $2.567M $2.070M
YoY Change 4.07% 24.01% -16.57%
Total Long-Term Liabilities $115.6M $113.7M $103.6M
YoY Change 9.47% 9.75% 4075.21%
TOTAL LIABILITIES
Total Short-Term Liabilities $42.37M $48.29M $49.34M
Total Long-Term Liabilities $115.6M $113.7M $103.6M
Total Liabilities $163.4M $168.1M $152.9M
YoY Change 6.16% 9.9% 14.5%
SHAREHOLDERS EQUITY
Retained Earnings -$526.5M -$524.0M -$471.4M
YoY Change 9.34% 11.17% 13.49%
Common Stock $55.00K $55.00K $48.00K
YoY Change 14.58% 14.58%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $124.6M $121.4M $50.45M
YoY Change
Total Liabilities & Shareholders Equity $288.0M $289.5M $203.4M
YoY Change 45.39% 42.34% -10.93%

Cashflow Statement

Concept 2013 Q4 2013 Q3 2012 Q3
OPERATING ACTIVITIES
Net Income -$2.500M -$21.29M -$12.42M
YoY Change -75.48% 71.46% -8.44%
Depreciation, Depletion And Amortization $2.950M $3.100M $2.590M
YoY Change 0.34% 19.69% -8.48%
Cash From Operating Activities -$3.520M $3.700M -$3.450M
YoY Change -37.03% -207.25% 315.66%
INVESTING ACTIVITIES
Capital Expenditures -$2.790M -$1.820M -$4.690M
YoY Change 36.1% -61.19% 42.99%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change
Cash From Investing Activities -$2.790M -$1.820M -$4.690M
YoY Change 36.1% -61.19% 43.43%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.130M 1.090M 1.430M
YoY Change 42.0% -23.78% 21.19%
NET CHANGE
Cash From Operating Activities -3.520M 3.700M -3.450M
Cash From Investing Activities -2.790M -1.820M -4.690M
Cash From Financing Activities 2.130M 1.090M 1.430M
Net Change In Cash -4.180M 2.970M -6.710M
YoY Change -31.92% -144.26% 129.79%
FREE CASH FLOW
Cash From Operating Activities -$3.520M $3.700M -$3.450M
Capital Expenditures -$2.790M -$1.820M -$4.690M
Free Cash Flow -$730.0K $5.520M $1.240M
YoY Change -79.38% 345.16% -49.39%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2013Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
15117000 USD
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
9361000 USD
CY2012Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
39921000 USD
CY2013Q3 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
41762000 USD
CY2012Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
33294000 USD
CY2013Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
34465000 USD
CY2012Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
19051000 USD
CY2013Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
30017000 USD
us-gaap Acquired Finite Lived Intangible Assets Weighted Average Useful Life
AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
P8Y
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
83000 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
7111000 USD
CY2012Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
525679000 USD
CY2013Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
645396000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7500000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9800000 USD
CY2013Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3000000 USD
CY2012Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2300000 USD
CY2012Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
6627000 USD
CY2013Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
7297000 USD
CY2013Q3 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
2447000 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
7958000 USD
CY2012Q3 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
2420000 USD
CY2013Q3 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
146000 USD
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
445000 USD
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
443000 USD
CY2012Q3 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
148000 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
7556000 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
8726000 USD
CY2012Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1400000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3800000 USD
CY2013Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1100000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
4600000 USD
CY2013Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8715231 shares
CY2012Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9810682 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8715231 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9810682 shares
CY2012Q4 us-gaap Assets
Assets
198059000 USD
CY2013Q3 us-gaap Assets
Assets
289496000 USD
CY2012Q4 us-gaap Assets Current
AssetsCurrent
109936000 USD
CY2013Q3 us-gaap Assets Current
AssetsCurrent
199686000 USD
CY2013Q3 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
2593000 USD
CY2012Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
0 USD
us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
0 USD
us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
9021000 USD
CY2012Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
0 USD
CY2013Q3 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
6092000 USD
CY2013Q3 us-gaap Capital Leased Assets Gross
CapitalLeasedAssetsGross
6500000 USD
CY2013Q3 us-gaap Capital Leases Future Minimum Payments Due
CapitalLeasesFutureMinimumPaymentsDue
10993000 USD
CY2013Q3 us-gaap Capital Leases Future Minimum Payments Due Current
CapitalLeasesFutureMinimumPaymentsDueCurrent
3815000 USD
CY2013Q2 us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
26523 shares
CY2013Q3 us-gaap Capital Leases Future Minimum Payments Due In Three Years
CapitalLeasesFutureMinimumPaymentsDueInThreeYears
2409000 USD
CY2013Q3 us-gaap Capital Leases Future Minimum Payments Due In Two Years
CapitalLeasesFutureMinimumPaymentsDueInTwoYears
3815000 USD
CY2013Q3 us-gaap Capital Leases Future Minimum Payments Remainder Of Fiscal Year
CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear
954000 USD
CY2013Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
153905000 USD
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
57293000 USD
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
93955000 USD
CY2012Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
63443000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
96612000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-30512000 USD
CY2012Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2013Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2013Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2013Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
54521310 shares
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
48359063 shares
CY2013Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
54521310 shares
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
48359063 shares
CY2013Q3 us-gaap Common Stock Value
CommonStockValue
55000 USD
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
48000 USD
CY2012 us-gaap Concentration Risk Percentage1
ConcentrationRiskPercentage1
0.19
us-gaap Concentration Risk Percentage1
ConcentrationRiskPercentage1
0.26
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
99168000 USD
CY2013Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
33708000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
86524000 USD
CY2012Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
30362000 USD
us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
171000 USD
CY2013Q3 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
-20000 USD
CY2012Q3 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
15000 USD
us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
78000 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
700000 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
18000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
65000 USD
CY2013Q2 us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
620122 shares
CY2013Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
32633000 USD
CY2012Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
40591000 USD
CY2013Q3 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
1560000 USD
CY2012Q4 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
2004000 USD
CY2012Q3 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
13000 USD
CY2013Q3 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
25000 USD
CY2012Q4 us-gaap Deferred Revenue
DeferredRevenue
5400000 USD
CY2013Q3 us-gaap Deferred Revenue
DeferredRevenue
600000 USD
CY2013Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
567000 USD
CY2012Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
5445000 USD
CY2013Q3 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
500000 USD
CY2012Q4 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
500000 USD
CY2013Q3 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
800000 USD
CY2012Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
700000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
8859000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
8092000 USD
CY2013Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.39
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.79
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.87
CY2012Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.26
CY2013Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
26600000 USD
CY2013Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
13746000 USD
CY2012Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
9937000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1966000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1401000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
7500000 USD
CY2013Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
32900000 USD
CY2012Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
32900000 USD
CY2012Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
22963000 USD
CY2013Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
19154000 USD
CY2011 us-gaap Finitelived Intangible Assets Acquired1
FinitelivedIntangibleAssetsAcquired1
32900000 USD
CY2012Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12731000 USD
CY2013Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
23530000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
38416000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
50525000 USD
CY2013Q3 us-gaap Goodwill
Goodwill
37536000 USD
CY2012Q4 us-gaap Goodwill
Goodwill
37536000 USD
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
CY2013Q3 us-gaap Gross Profit
GrossProfit
27395000 USD
CY2012Q3 us-gaap Gross Profit
GrossProfit
24390000 USD
us-gaap Gross Profit
GrossProfit
79383000 USD
us-gaap Gross Profit
GrossProfit
67017000 USD
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0 USD
CY2013Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-21285000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-41530000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-42220000 USD
CY2012Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-12389000 USD
CY2012Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
28000 USD
CY2013Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
254000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
143000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3251000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
9276000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
5113000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-4878000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1444000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-9472000 USD
us-gaap Interest And Debt Expense
InterestAndDebtExpense
12970000 USD
CY2013Q3 us-gaap Interest And Debt Expense
InterestAndDebtExpense
3999000 USD
us-gaap Interest And Debt Expense
InterestAndDebtExpense
11728000 USD
CY2012Q3 us-gaap Interest And Debt Expense
InterestAndDebtExpense
3949000 USD
CY2013Q3 us-gaap Interest Expense
InterestExpense
100000 USD
us-gaap Interest Expense
InterestExpense
100000 USD
us-gaap Interest Expense Debt
InterestExpenseDebt
12203000 USD
CY2013Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
3940000 USD
us-gaap Interest Expense Debt
InterestExpenseDebt
13082000 USD
CY2012Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
4117000 USD
CY2012Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
11785000 USD
CY2013Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
5068000 USD
CY2013Q3 us-gaap Inventory Net
InventoryNet
5395000 USD
CY2012Q4 us-gaap Inventory Net
InventoryNet
14867000 USD
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
10.30
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
19.36
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
198059000 USD
CY2013Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
321000 USD
CY2012Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
1487000 USD
CY2012Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1595000 USD
CY2013Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
6000 USD
CY2012Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
31000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
83000 USD
CY2013Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
27000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
91000 USD
CY2013Q3 us-gaap Liabilities
Liabilities
168070000 USD
CY2012Q4 us-gaap Liabilities
Liabilities
153883000 USD
CY2013Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
289496000 USD
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
48286000 USD
CY2013Q3 us-gaap Liabilities Current
LiabilitiesCurrent
48294000 USD
CY2012Q4 us-gaap Long Term Debt
LongTermDebt
118159000 USD
CY2013Q3 us-gaap Long Term Debt
LongTermDebt
111117000 USD
CY2013Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
0 USD
CY2012Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
14429000 USD
CY2012Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
103730000 USD
CY2013Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
111117000 USD
us-gaap Nature Of Operations
NatureOfOperations
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nature of the Business</font></div><div style="line-height:120%;padding-top:12px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is primarily engaged in the development, manufacturing and sale of its proprietary OmniPod Insulin Management System (the &#8220;OmniPod System&#8221;), an innovative, discreet and easy-to-use insulin infusion system for people with insulin-dependent diabetes. The OmniPod System is the only commercially-available insulin infusion system of its kind. The OmniPod System features a unique disposable tubeless OmniPod which is worn on the body for approximately three days at a time and the handheld, wireless Personal Diabetes Manager (&#8220;PDM&#8221;). Conventional insulin pumps require people with insulin-dependent diabetes to learn to use, manage and wear a number of cumbersome components, including up to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">42</font><font style="font-family:inherit;font-size:10pt;"> inches of tubing. In contrast, the OmniPod System features two discreet, easy-to-use devices that eliminate the need for a bulky pump, tubing and separate blood glucose meter, provides for virtually pain-free automated cannula insertion, communicates wirelessly and integrates a blood glucose meter. </font></div><div style="line-height:120%;padding-top:12px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2011, the Company acquired Neighborhood Holdings, Inc. and its wholly-owned subsidiaries (collectively, &#8220;Neighborhood Diabetes&#8221;) in order to support the sales of the OmniPod System, expand the Company&#8217;s full suite diabetes management product offerings and obtain access to a larger number of insulin dependent patients. Through Neighborhood Diabetes, the Company is able to provide customers with blood glucose testing supplies, traditional insulin pumps, pump supplies and pharmaceuticals and has the ability to process claims as either durable medical equipment or through pharmacy benefits.</font></div><div style="line-height:120%;padding-top:12px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company began commercial sale of the OmniPod System in the United States in October 2005. The Company has also expanded the availability of the OmniPod System internationally through its partnership with Ypsomed Distribution AG (&#8220;Ypsomed&#8221;) and GlaxoSmithKline (&#8220;GSK&#8221;). In January 2010, the Company entered into a distribution agreement with Ypsomed pursuant to which Ypsomed became the exclusive distributor of the OmniPod System in multiple countries. In February 2011, the Company entered into a distribution agreement with GSK pursuant to which GSK became the exclusive distributor of the OmniPod System in Canada. </font></div><div style="line-height:120%;padding-top:12px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2011, the Company received CE Mark approval, and in December 2012 the Company received 510(k) clearance by the FDA for its new OmniPod System. The new OmniPod System is more than one-third smaller and one-quarter lighter than the original model, while maintaining the same features and operating capabilities. The Company began selling the new OmniPod System in certain countries in Europe through Ypsomed in 2012. The Company began selling the new OmniPod System to new customers in the U.S. during the first quarter of 2013 and began converting the existing customer base in the second quarter of 2013. By the end of the third quarter, the Company completely transitioned its production to the new OmniPod System.</font></div></div>
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1890000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
94263000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4517000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-8936000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23466000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
6866000 USD
us-gaap Net Income Loss
NetIncomeLoss
-42474000 USD
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
25.54
us-gaap Operating Expenses
OperatingExpenses
96902000 USD
CY2013Q3 us-gaap Operating Expenses
OperatingExpenses
44708000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-29885000 USD
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-17313000 USD
us-gaap Net Income Loss
NetIncomeLoss
-41673000 USD
CY2012Q3 us-gaap Net Income Loss
NetIncomeLoss
-12417000 USD
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-21290000 USD
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2012Q3 us-gaap Operating Expenses
OperatingExpenses
32861000 USD
us-gaap Operating Expenses
OperatingExpenses
108724000 USD
CY2012Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-8471000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-29341000 USD
CY2013Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1591000 USD
CY2013Q3 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
1134000 USD
CY2013Q3 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
96000 USD
CY2013Q3 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
361000 USD
us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
0 USD
us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
2511000 USD
CY2013Q3 us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
2511000 USD
CY2012Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2202000 USD
CY2013Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1721000 USD
CY2013Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2567000 USD
CY2012Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1867000 USD
CY2012Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3918000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-11645000 USD
CY2013Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3972000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-12879000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1252000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
2565000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4517000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
8936000 USD
CY2013Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2012Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2012Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2013Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2012Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2012Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2012Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2013Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2012Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4482000 USD
CY2013Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5921000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
99164000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3142000 USD
CY2013Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
97800000 USD
CY2012Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1992000 USD
CY2013Q3 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
2809000 USD
CY2013Q2 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
2401000 USD
CY2012Q3 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1806000 USD
CY2011Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1960000 USD
CY2012Q2 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1822000 USD
CY2012Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
863000 USD
CY2013Q3 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
1047000 USD
CY2013Q3 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
1762000 USD
CY2012Q4 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
1129000 USD
CY2012Q3 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
661000 USD
us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
2021000 USD
CY2013Q3 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
702000 USD
us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
1954000 USD
us-gaap Product Warranty Accrual Warranties Issued
ProductWarrantyAccrualWarrantiesIssued
1867000 USD
CY2012Q3 us-gaap Product Warranty Accrual Warranties Issued
ProductWarrantyAccrualWarrantiesIssued
645000 USD
CY2013Q3 us-gaap Product Warranty Accrual Warranties Issued
ProductWarrantyAccrualWarrantiesIssued
1110000 USD
us-gaap Product Warranty Accrual Warranties Issued
ProductWarrantyAccrualWarrantiesIssued
2771000 USD
CY2013Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
31399000 USD
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
25422000 USD
us-gaap Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
P5Y
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
3942000 USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
2321000 USD
us-gaap Repayments Of Debt
RepaymentsOfDebt
0 USD
us-gaap Repayments Of Debt
RepaymentsOfDebt
2000000 USD
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
0 USD
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
336000 USD
CY2013Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5771000 USD
CY2012Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6559000 USD
dei Document Type
DocumentType
10-Q
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15341000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18512000 USD
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-481551000 USD
CY2013Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-524025000 USD
CY2013Q1 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
20.75
CY2013Q3 us-gaap Sales Revenue Net
SalesRevenueNet
61103000 USD
us-gaap Sales Revenue Net
SalesRevenueNet
153541000 USD
CY2012Q3 us-gaap Sales Revenue Net
SalesRevenueNet
54752000 USD
us-gaap Sales Revenue Net
SalesRevenueNet
178551000 USD
CY2013Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
15407000 USD
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
42858000 USD
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
39974000 USD
CY2012Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
13571000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
9800000 USD
CY2007Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
535000 shares
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1302995 shares
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
12.70
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
10930000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
53371 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
276900 shares
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
43499000 USD
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2130560 shares
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2502190 shares
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
13.51
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
15.82
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
38633000 USD
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
1827646 shares
CY2013Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
30676000 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y9M15D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y9M50D
us-gaap Stock Issued1
StockIssued1
13000000 USD
us-gaap Stock Issued1
StockIssued1
0 USD
CY2013Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
4715000 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
595159 shares
CY2013Q3 us-gaap Stockholders Equity
StockholdersEquity
121426000 USD
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
44176000 USD
CY2013Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 USD
us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates in Preparation of Financial Statements</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expense during the reporting periods. The most significant estimates used in these financial statements include the valuation of stock-based compensation expense, accounts receivable, inventories, goodwill, deferred revenue and equity instruments, the lives of property and equipment and intangible assets, as well as warranty and doubtful accounts allowance reserve calculations. Actual results may differ from those estimates.</font></div></div>
CY2012Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
48041392 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
53786974 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
47825136 shares
CY2013Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
54458364 shares
podd Capital Lease Effective Interest Rate
CapitalLeaseEffectiveInterestRate
0.17
podd Capital Lease Term
CapitalLeaseTerm
P36M
CY2012Q3 podd Debt Instrument Stated Coupon Rate Interest Expense
DebtInstrumentStatedCouponRateInterestExpense
1549000 USD
podd Debt Instrument Stated Coupon Rate Interest Expense
DebtInstrumentStatedCouponRateInterestExpense
4356000 USD
CY2013Q3 podd Debt Instrument Stated Coupon Rate Interest Expense
DebtInstrumentStatedCouponRateInterestExpense
1347000 USD
podd Debt Instrument Stated Coupon Rate Interest Expense
DebtInstrumentStatedCouponRateInterestExpense
4647000 USD
CY2012Q3 podd Dollarequivalentofsharesissuedatconversion
Dollarequivalentofsharesissuedatconversion
0 USD
podd Dollarequivalentofsharesissuedatconversion
Dollarequivalentofsharesissuedatconversion
0 USD
podd Dollarequivalentofsharesissuedatconversion
Dollarequivalentofsharesissuedatconversion
325000 USD
CY2013Q3 podd Dollarequivalentofsharesissuedatconversion
Dollarequivalentofsharesissuedatconversion
0 USD
podd Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities
IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities
8657000 USD
podd Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities
IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities
16722000 USD
CY2012Q1 podd Maximum Annualauthorized Share Increaes
MaximumAnnualauthorizedShareIncreaes
725000 shares
CY2012Q4 podd Number Of Customers With Greater Than Ten Percent Accounts Receivable Balance
NumberOfCustomersWithGreaterThanTenPercentAccountsReceivableBalance
2 customer
CY2013Q3 podd Number Of Customers With Greater Than Ten Percent Accounts Receivable Balance
NumberOfCustomersWithGreaterThanTenPercentAccountsReceivableBalance
2 customer
CY2013Q3 podd Number Of Financial Institution
NumberOfFinancialInstitution
2 location
CY2013Q3 podd Number Of Inches Of Tubing In Conventional Insulin Pump
NumberOfInchesOfTubingInConventionalInsulinPump
42 in
CY2013Q3 podd Number Of Single Source Suppliers
NumberOfSingleSourceSuppliers
1 customer
CY2012Q4 podd Number Of Single Source Suppliers
NumberOfSingleSourceSuppliers
1 customer
CY2013Q1 podd Proceeds Of Issuance Of Common Stock Net Of Expenses
ProceedsOfIssuanceOfCommonStockNetOfExpenses
92800000 USD
podd Product Warranty Term
ProductWarrantyTerm
P4Y
podd Renewal Option Terms Additional Period
RenewalOptionTermsAdditionalPeriod
P5Y
podd Return Period
ReturnPeriod
P45D
podd Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeitures
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitures
0.16
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
dei Document Period End Date
DocumentPeriodEndDate
2013-09-30
dei Entity Central Index Key
EntityCentralIndexKey
0001145197
CY2013Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
54539340 shares
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Registrant Name
EntityRegistrantName
INSULET CORP
dei Trading Symbol
TradingSymbol
PODD

Files In Submission

Name View Source Status
0001145197-13-000035-index-headers.html Edgar Link pending
0001145197-13-000035-index.html Edgar Link pending
0001145197-13-000035.txt Edgar Link pending
0001145197-13-000035-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
podd-20130930.xml Edgar Link completed
podd-20130930.xsd Edgar Link pending
podd-20130930_cal.xml Edgar Link unprocessable
podd-20130930_def.xml Edgar Link unprocessable
podd-20130930_lab.xml Edgar Link unprocessable
podd-20130930_pre.xml Edgar Link unprocessable
podd-2013x09x30x10xq.htm Edgar Link pending
podd-ex101_2013930xq3.htm Edgar Link pending
podd-ex311_2013930xq3.htm Edgar Link pending
podd-ex312_2013930xq3.htm Edgar Link pending
podd-ex321_2013930xq3.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending